Inhibiting ERK dimerization ameliorates BRAF‑driven anaplastic thyroid cancer.
Loading...
Identifiers
Publication date
2022
Start date of the public exhibition period
End date of the public exhibition period
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Cellular and Molecular Life Sciences
Share
Abstract
Background RAS-to-ERK signaling is crucial for the onset and progression of advanced thyroid carcinoma, and blocking
ERK dimerization provides a therapeutic beneft in several human carcinomas. Here we analyzed the efects of DEL-22379, a
relatively specifc ERK dimerization inhibitor, on the activation of the RAS-to-ERK signaling cascade and on tumor-related
processes in vitro and in vivo.
Methods We used a panel of four human anaplastic thyroid carcinoma (ATC) cell lines harboring BRAF or RAS mutations
to analyze ERK dynamics and tumor-specifc characteristics. We also assessed the impact of DEL-22379 on the transcriptional landscape of ATC cell lines using RNA-sequencing and evaluated its therapeutic efcacy in an orthotopic mouse
model of ATC.
Results DEL-22379 impaired upstream ERK activation in BRAF- but not RAS-mutant cells. Cell viability and metastasisrelated processes were attenuated by DEL-22379 treatment, but mostly in BRAF-mutant cells, whereas in vivo tumor growth
and dissemination were strongly reduced for BRAF-mutant cells and mildly reduced for RAS-mutant cells. Transcriptomics
analyses indicated that DEL-22379 modulated the transcriptional landscape of BRAF- and RAS-mutant cells in opposite
directions.
Conclusions Our fndings establish that BRAF- and RAS-mutant thyroid cells respond diferentially to DEL-22379, which
cannot be explained by the previously described mechanism of action of the inhibitor. Nonetheless, DEL-22379 demonstrated
signifcant anti-tumor efects against BRAF-mutant cells in vivo with an apparent lack of toxicity, making it an interesting
candidate for the development of combinatorial treatments. Our data underscore the diferences elicited by the specifc driver
mutation for thyroid cancer onset and progression, which should be considered for experimental and clinical approaches.
Doctoral program
Description
Keywords
Thyroid cancer